About
Titles
Research Associate
Education & Training
- BS
- University of New England, Medical Biology (2008)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Heather Lazowski's published research.
Publications Timeline
A big-picture view of Heather Lazowski's research output by year.
Lynn Tanoue, MD, MBA
Roy S. Herbst, MD, PhD
Daniel Boffa, MD
David Rimm, MD, PhD
Dejian Zhao, PhD
Fangyong Li, MS, MPH
4Publications
11Citations
Publications
2024
Trends and predictors of Quality of Life in lung cancer survivors
Bade B, Zhao J, Li F, Tanoue L, Lazowski H, Alfano C, Silvestri G, Irwin M. Trends and predictors of Quality of Life in lung cancer survivors. Lung Cancer 2024, 191: 107793. PMID: 38640687, DOI: 10.1016/j.lungcan.2024.107793.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsFunctional Assessment of Cancer Therapy - LungNon-small cell lung cancerHR-QOL scoresLung cancer survivorsHR-QOLAdvanced stage non-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerQuality of lifeCancer survivorsPhysical activityCell lung cancerEarly-stage diseasePredictors of quality of lifeHealth-related quality of lifeFollow-upHealth-related qualityHealthy weight maintenancePerformance statusAdvanced-stage non-small cell lung cancerLung cancerClinical significanceAssociated with older ageDiagnosed NSCLCTreatment-related side effects
2022
APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma
Cannataro VL, Kudalkar S, Dasari K, Gaffney SG, Lazowski HM, Jackson LK, Yildiz I, Das RK, Rothberg BE, Anderson KS, Townsend JP. APOBEC mutagenesis and selection for NFE2L2 contribute to the origin of lung squamous-cell carcinoma. Lung Cancer 2022, 171: 34-41. PMID: 35872531, PMCID: PMC10126952, DOI: 10.1016/j.lungcan.2022.07.004.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCytidine deaminationMutagenic processesDefective homologous recombinationGenomic sequencesHomologous recombinationAttractive potential targetAPOBEC mutagenesisLung squamous cell carcinomaDeamination activityCancer cell growthAPOBEC proteinsAPOBEC activityCell growthCellular proliferationNFE2L2MutationsMolecular investigationsCancer effectsPotential targetMolecular variantsAPOBECSurvival of cancerSquamous cell carcinomaDeaminationVariantsRASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
Hunihan L, Zhao D, Lazowski H, Li M, Qian Y, Abriola L, Surovtseva YV, Muthusamy V, Tanoue LT, Rothberg BE, Schalper KA, Herbst RS, Wilson FH. RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. Clinical Cancer Research 2022, 28: 3091-3103. PMID: 35247929, PMCID: PMC9288503, DOI: 10.1158/1078-0432.ccr-21-4291.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLung adenocarcinomaSmoking historyPack-year smoking historyMinimal smoking historySubset of patientsPancreatic ductal adenocarcinoma cell linesPotential treatment strategyTight junction protein occludinJunction protein occludinWhole-exome sequencingAdenocarcinoma cell lineAdvanced malignanciesCancer Genome AtlasRaf-MEKAdvanced tumorsMultiple malignanciesTreatment strategiesKRAS mutationsTherapeutic strategiesTherapeutic targetOncogenic RAS SignalingRelated commentaryOncogenic driversMEK inhibitionOncogenic alterations
2017
P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers
Rothberg B, Das R, Jackson L, Lazowski H, Bai Y, O'Neill D, Roberts S, Rothberg J, Herbst R, Kim A, Boffa D, Rimm D, Detterbeck F, Tanoue L. P1.05-017 The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early-Stage Lung Adenocarcinomas Topic: Translational Research and Biomarkers. Journal Of Thoracic Oncology 2017, 12: s623-s624. DOI: 10.1016/j.jtho.2016.11.801.Peer-Reviewed Original ResearchCitations